Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	29.45B -15.9%
Revenue (ttm)	12.41B -8.9%
Net Income	1.93B -22.9%
EPS	2.17 -21.3%
Shares Out	n/a
PE Ratio	15.23
Forward PE	11.97
Dividend	2.83 (12.89%)
Ex-Dividend Date	Oct 14, 2026

Volume	623,880
Open	23.18
Previous Close	22.72
Day's Range	21.52 - 23.18
52-Week Range	19.80 - 35.50
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2025, HKG:1513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error